Literature DB >> 2465404

Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release.

W E Robinson1, D C Montefiori, D H Gillespie, W M Mitchell.   

Abstract

Antibody-dependent enhancement (ADE) of human immunodeficiency virus type 1 (HIV-1) infection in vitro has been described recently and was shown to occur by two mechanisms: either participation of the alternative pathway of complement or to involve an Fc receptor-mediated, complement-independent mechanism. Complement-mediated ADE results in an accelerated cytopathic effect in target cells that can abrogate the protective properties of neutralizing antibodies. This study characterizes the surface antigens of MT-2 cells using flow cytometric analysis and shows that these cells express high levels of both CD4 and complement receptor type 2 (CR2) while several CD4+ cell lines that do not demonstrate complement-mediated ADE lack high levels of complement receptors. Further, utilizing MT-2 cell cultures, it is demonstrated that complement-mediated ADE of HIV-1 infection is conferred by the sera from more than 80% of HIV-1 antibody-positive individuals (N = 85). Complement-mediated ADE of HIV-1 infection causes an acceleration of several parameters indicative of HIV-1 infection in vitro including increased HIV-1 antigen synthesis as detected by indirect immunofluorescence, RNA accumulation as measured by a solution hybridization protocol, reverse transcriptase release, and progeny virus production.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2465404

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  50 in total

1.  Click dimers to target HIV TAR RNA conformation.

Authors:  Sunil Kumar; Patrick Kellish; W Edward Robinson; Deyun Wang; Daniel H Appella; Dev P Arya
Journal:  Biochemistry       Date:  2012-03-09       Impact factor: 3.162

2.  Neutralizing antibodies and antigens in AIDS.

Authors:  S G Norley; R Kurth
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 4.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

5.  New FDA drug approval policies and HIV vaccine development.

Authors:  W K Mariner
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

6.  Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase.

Authors:  W E Robinson; M G Reinecke; S Abdel-Malek; Q Jia; S A Chow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 7.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Authors:  Evgeny Shmelkov; Arthur Nadas; Timothy Cardozo
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

9.  Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid.

Authors:  Ryan Reinke; Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line.

Authors:  G S Gras; D Dormont
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.